Two COVID-19 vaccines are already being given to Americans. But what about AstraZeneca (NASDAQ: AZN), which announced interim efficacy results from a late-stage clinical study of its coronavirus vaccine candidate in November? Could the British drugmaker’s treatment still succeed? In this Motley Fool Live video recorded on Dec. 18, 2020, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com writer Keith Speights discuss what investors should know about AstraZeneca’s next steps.
Could AstraZeneca’s COVID Vaccine Still Succeed?
Latest from Blog
Image source: The Motley Fool. Citizens Financial Group Inc (NYSE: CFG)Q4 2020 Earnings CallJan 20, 2021, 8:00 a.m.…
Image source: The Motley Fool. UnitedHealth Group (NYSE: UNH)Q4 2020 Earnings CallJan 20, 2021, 8:45 a.m. ET Operator…
The stock market pushed sharply higher on Wednesday, sending the Dow Jones Industrial Average (DJINDICES: ^DJI),…
Image source: The Motley Fool. BOK Financial Corp (NASDAQ: BOKF)Q4 2020 Earnings CallJan 20, 2021, 10:00 a.m. ET…
Image source: The Motley Fool. Pinnacle Financial Partners Inc (NASDAQ: PNFP)Q4 2020 Earnings CallJan 20, 2021, 9:30 a.m.…